Assessment of Early-detection Based on Liquid Biopsy in Lymphoid Malignancies

Inclusion Criteria for All Participants:

• Age 40-75 years at the day of consenting to the study.

• Able to provide a written informed consent.

Additional Inclusion Criteria for Cancer Participants:

• No prior cancer treatment (local or systematic) prior to blood draw.

• High suspicious or pathologically confirmed lymphoid malignancies within 42 days prior to blood draw.

Additional Inclusion Criteria for Benign Disease Participants:

• No prior radical treatment of the benign diseases prior to study blood draw

• Pathologically confirmed diagnosis of lymphoid benign diseases within 90 days prior to blood draw.

Exclusion Criteria for All Participants:

• Insufficient qualified blood samples.

• During pregnancy or lactation.

• Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant.

• Recipient of blood transfusion within 7 days prior to blood draw.

• Recipient of anti-tumor drugs to treat non-cancer diseases within 30 days prior to blood draw, such as rheumatic drugs (methotrexate, cyclophosphamide, or azathioprine), or endocrine drugs (tamoxifen).

Additional Exclusion Criteria for Cancer Participants:

• With other known malignant tumors or multiple primary tumors.

• Lymphoid malignancies unable to comfirmed by imaging tests or pathological cancer diagnosis within 42 days after the blood draw.

Additional Exclusion Criteria for Benign Disease Participants:

• With other known malignant tumors or comfirmed lymphoid malignancies.

• Lymphoid benign diseases unable to comfirmed by imaging tests or pathological cancer diagnosis within 42 days after the blood draw.